These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 26084582)

  • 1. Type 2 diabetes in children and adolescents on atypical antipsychotics.
    Pramyothin P; Khaodhiar L
    Curr Diab Rep; 2015 Aug; 15(8):53. PubMed ID: 26084582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents.
    Klein DJ; Cottingham EM; Sorter M; Barton BA; Morrison JA
    Am J Psychiatry; 2006 Dec; 163(12):2072-9. PubMed ID: 17151157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
    Stahl SM; Mignon L; Meyer JM
    Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bridging the gap from evidence to policy and practice: reducing the progression to metabolic syndrome for children and adolescents on antipsychotic medication.
    Eapen V; Shiers D; Curtis J
    Aust N Z J Psychiatry; 2013 May; 47(5):435-42. PubMed ID: 23047958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The implications of weight changes with antipsychotic treatment.
    Sussman N
    J Clin Psychopharmacol; 2003 Jun; 23(3 Suppl 1):S21-6. PubMed ID: 12832946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gaining: pediatric patients and use of atypical antipsychotics.
    Towbin KE
    Am J Psychiatry; 2006 Dec; 163(12):2034-6. PubMed ID: 17151148
    [No Abstract]   [Full Text] [Related]  

  • 7. Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management.
    Stigler KA; Potenza MN; Posey DJ; McDougle CJ
    Paediatr Drugs; 2004; 6(1):33-44. PubMed ID: 14969568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antipsychotics and metabolic abnormalities in children and adolescents: a review of the literature and some recommendations].
    Overbeek WA; de Vroede MA; Lahuis BE; Hillegers MH; de Graeff-Meeder ER
    Tijdschr Psychiatr; 2010; 52(5):311-20. PubMed ID: 20458678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes.
    Silvestre JS; Prous J
    Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):289-304. PubMed ID: 16082416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schizophrenia, obesity, and antipsychotic medications: what can we do?
    Citrome L; Vreeland B
    Postgrad Med; 2008 Jul; 120(2):18-33. PubMed ID: 18654065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative risk of new-onset diabetes following commencement of antipsychotics in New Zealand: a population-based clustered multiple baseline time series design.
    Currie O; Williman J; Mangin D; McKinnon-Gee B; Bridgford P
    BMJ Open; 2019 Feb; 9(2):e022984. PubMed ID: 30796116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.
    McIntyre RS; Jerrell JM
    Arch Pediatr Adolesc Med; 2008 Oct; 162(10):929-35. PubMed ID: 18838645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications.
    Faulkner G; Cohn TA
    Can J Psychiatry; 2006 Jul; 51(8):502-11. PubMed ID: 16933587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Challenges of the use of antipsychotics in children and adolescents].
    Portnova AA; Sivolap YP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(11):123-127. PubMed ID: 31851183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic syndrome with the atypical antipsychotics.
    Pramyothin P; Khaodhiar L
    Curr Opin Endocrinol Diabetes Obes; 2010 Oct; 17(5):460-6. PubMed ID: 20717020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of atypical antipsychotic drug-induced weight gain: focus on metformin.
    Miller LJ
    Pharmacotherapy; 2009 Jun; 29(6):725-35. PubMed ID: 19476423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs.
    Newcomer JW
    J Clin Psychiatry; 2004; 65 Suppl 18():36-46. PubMed ID: 15600383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical antipsychotics and diabetes mellitus.
    Lichiardopol R
    Rom J Intern Med; 2004; 42(2):301-12. PubMed ID: 15529621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of diabetes in children and adolescents exposed to antipsychotics: a nationwide 12-year case-control study.
    Nielsen RE; Laursen MF; Vernal DL; Bisgaard C; Jakobsen H; Steinhausen HC; Correll CU
    J Am Acad Child Adolesc Psychiatry; 2014 Sep; 53(9):971-979.e6. PubMed ID: 25151420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.